Loading...
Market
What will Pfizer's next steps be after Oxbryta withdrawal by March 31, 2025?
2
Resolution / Starting Odds
Introduce a new sickle cell treatment • 25%
Acquire another company with a sickle cell treatment • 25%
Exit the sickle cell treatment market • 25%
No major action • 25%
Official Pfizer announcements or news reports
Story
Pfizer Withdraws Sickle Cell Treatment Oxbryta from Global Markets Due to Safety Concerns, $5.4 Billion Acquisition Impacted
Sep 25, 2024, 09:30 PM
Pfizer Inc. announced it is voluntarily withdrawing all lots of its sickle cell disease treatment, Oxbryta (voxelotor), from worldwide markets due to safety concerns. The decision follows data indicating an imbalance in vaso-occlusive crises and fatal events associated with the drug. Oxbryta was acquired by Pfizer in a $5.4 billion deal with Global Blood Therapeutics in 2022.
View original story
Similar markets
No action taken • 25%
Warning issued • 25%
Fine imposed • 25%
Other sanctions • 25%
Yes • 50%
No • 50%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Pfizer wins the appeal • 25%
AstraZeneca wins the appeal • 25%
Settlement reached before appeal decision • 25%
Appeal dismissed • 25%
File an appeal • 25%
Submit new data • 25%
Withdraw application • 25%
Other • 25%
Patent infringement lawsuit • 25%
Settlement agreement • 25%
Licensing agreement • 25%
No major legal action • 25%
